Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Change in Receivables (2021 - 2025)

Pulse Biosciences (PLSE) has 5 years of Change in Receivables data on record, last reported at $259000.0 in Q4 2025.

  • For Q4 2025, Change in Receivables changed N/A year-over-year to $259000.0; the TTM value through Dec 2025 reached $274000.0, changed N/A, while the annual FY2025 figure was $274000.0, N/A changed from the prior year.
  • Change in Receivables reached $259000.0 in Q4 2025 per PLSE's latest filing, up from $1000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $259000.0 in Q4 2025 and bottomed at -$107000.0 in Q2 2023.
  • Average Change in Receivables over 5 years is $2631.6, with a median of -$3000.0 recorded in 2022.
  • Peak YoY movement for Change in Receivables: tumbled 723.08% in 2023, then surged 600.0% in 2024.
  • A 5-year view of Change in Receivables shows it stood at -$22000.0 in 2021, then skyrocketed by 77.27% to -$5000.0 in 2022, then soared by 200.0% to $5000.0 in 2023, then plummeted by 40.0% to $3000.0 in 2024, then skyrocketed by 8533.33% to $259000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were $259000.0 in Q4 2025, $1000.0 in Q3 2025, and $7000.0 in Q2 2025.